(C) 2013 Elsevier B.V. All rights reserved.”
“Objective: A neuropathic pain (NP) questionnaire may facilitate the identification of a neuropathic component to osteoarthritis (OA) pain. An existing questionnaire, the painDETECT, was modified

for use in knee OA and administered to measure the prevalence and correlates of NP symptoms among adults with this VX-770 in vitro condition.

Method: Sensibility of the modified painDETECT (mPD-Q) was assessed in 20 OA subjects followed by mail administration in an established knee OA cohort. NP symptoms were defined using a previously established, painDETECT cut-point. Correlates of NP symptoms, including OA severity (Western Ontario and McMaster Universities Osteoarthritis Index, Von Korff Chronic Pain Grade pain subscale score), psychological factors (Centre for Epidemiological Studies Depression Scale, Pain Catastrophizing Scale), and concomitant medical LY2606368 conditions, were evaluated using logistic regression. Construct validity of the mPD-Q was evaluated through co-administration with another NP questionnaire (S-LANSS).

Results: The mPD-Q had face and content validity. Of 259 eligible cohort members, 171 (66%) completed the questionnaire; 28% had NP symptoms on the mPD-Q (19% among those without neurological conditions). Independent correlates of NP symptoms were: pain intensity (adjusted

odds ratio [OR] = 2.1 per 10 unit increase, P < 0.0001), the presence of referred back/hip pain (adjusted OR = 2.9, P=0.024), number of painful joints (OR = 1.2, P=0.20) and one or more self-reported neurological condition (OR = 3.0, P=0.026).

Conclusions: Among older adults with chronic symptomatic knee OA, over one-quarter had NP symptoms localized to their knees using the mPD-Q, The mPD-Q may facilitate the identification GW4869 cell line of a neuropathic component to pain in adults with knee OA who may benefit from further evaluation and/or treatment for NP. (C) 2011 Osteoarthritis Research

Society International. Published by Elsevier Ltd. All rights reserved.”
“Stomach cancer is still one of the most prevalent malignancies and is the main cause of cancer deaths worldwide. The outcome for patients with metastasis, as well as for those with tumor recurrence, is dismal, with median survival time not greater than a year. Patients with unresectable locally advanced or metastatic lesions have been treated with systemic chemotherapy, and several randomized studies have demonstrated the benefit of chemotherapy compared with best supportive care. Recently, randomized phase III trials have presented a benefit of second-line chemotherapy compared with supportive care alone. However, it is not known at present which drug is the most effective in this setting.